Marizomib Designated Orphan Drug Status for Multiple Myeloma

Share this content:
Marizomib Designated Orphan Drug Status for Multiple Myeloma
Marizomib Designated Orphan Drug Status for Multiple Myeloma

Triphase Accelerator announced that the FDA has granted marizomib Orphan Drug designation for the treatment of multiple myeloma. Marizomib is a novel, highly potent proteasome inhibitor that is also being evaluated for the treatment of other cancer indications.

RELATED: Hematologic Cancers Resource Center

An intravenous (IV) formulation of marizomib has been evaluated in more than 230 patients across four Phase 1/2 studies, either as a single agent or in combination with dexamethasone or an HDAC inhibitor. Triphase is currently evaluating the IV formulation in an ongoing Phase 2 clinical trial in combination with dexamethasone in a highly refractory multiple myeloma population, including those refractory to carfilzomib.  It is also being tested in a Phase 1/2 study in combination with pomalidomide and dexamethasone in relapsed and

For more information call (858) 242-1513 or visit

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs